EMBOLD study

Embold is a pioneering health brand dedicated to advancing treatment options for children suffering from early-onset SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEE). At the heart of their mission is the EMBOLD study, which explores the safety and efficacy of relutrigine, an investigational medication designed to regulate sodium flow in brain cells, targeting the overactive channels responsible for seizures. This innovative treatment offers the potential for improved seizure control while minimizing side effects.

The EMBOLD study provides families with flexible participation options, allowing them to engage at home, in-clinic, or through a hybrid model. Participants receive comprehensive support, including coverage for travel and related expenses. Initial results are promising, showing significant reductions in seizure frequency and improved quality of life for many children. With a focus on continuous improvement and access to care, Embold seeks to empower families and enhance the lives of children affected by these challenging conditions. Stay informed about their advancements and opportunities for participation.